Literature DB >> 9696010

Tolerance and latent cellular rejection in long-term liver transplant recipients.

T Wong1, K T Nouri-Aria, J Devlin, B Portmann, R Williams.   

Abstract

Tolerance develops in a proportion of long-term liver transplant recipients but currently cannot be identified before an attempt at withdrawal from immunosuppression therapy. In the present study, we have examined the immunophenotypic characteristics of the cellular infiltrate in portal tracts and lobules as observed in liver biopsy specimens in relation to the outcome of subsequent withdrawal from immunosuppression therapy. Cryostat biopsy specimens from 27 long-term recipients before drug withdrawal, and from 10 patients with recent transplants who were having acute rejection, were analyzed. Immunohistochemical staining was performed for CD3+ (pan T cell), CD8+ (cytotoxic), CD4+ (helper), CD45RO+ (memory), CD45RA+ (naive), CD56+ (natural killer), CD68+ (macrophage), and CD8+ perforin+ cells. Fewer CD8+ and CD3+ cells were present in the lobular areas of biopsy specimens from patients who were successfully withdrawn from immunosuppression therapy (n = 6) compared with biopsy specimens from patients with nontolerant grafts (n = 9; 15 vs. 23 cells/high-power field [hpf] [P < .01] and 16 vs. 26 cells/hpf [P < .03], respectively) or biopsy specimens obtained during acute rejection (15 vs. 31 cells/hpf [P < .01] and 16 vs. 32 cells/hpf [P < .01]). Cell frequencies in the biopsy specimens of nontolerant long-term patients were similar to those found with acute rejection. Immunophenotyping the lobular inflammation within long-term liver allografts assists in identifying those patients in whom drug withdrawal is likely to be unsuccessful and in whom it is postulated a form of inactive, latent cellular rejection exists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696010     DOI: 10.1002/hep.510280223

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.

Authors:  Alberto Sánchez-Fueyo; Terry B Strom
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

Review 2.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

3.  Zinc finger protein A20 protects rats against chronic liver allograft dysfunction.

Authors:  Jie Yang; Ming-Qing Xu; Lu-Nan Yan; Xiao-Bo Chen; Jiao Liu
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 4.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

5.  Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.

Authors:  Josh Levitsky; Joshua Miller; Edward Wang; Anne Rosen; Cathy Flaa; Michael Abecassis; James Mathew; Anat Tambur
Journal:  Hum Immunol       Date:  2009-01-12       Impact factor: 2.850

6.  Serial assessment of immune status by circulating CD8 effector T cell frequencies for posttransplant infectious complications.

Authors:  Shinji Uemoto; Kazue Ozawa; Hiroto Egawa; Yasutsugu Takada; Hiroshi Sato; Satoshi Teramukai; Mureo Kasahara; Kohei Ogawa; Masako Ono; Kenji Takai; Masanori Fukushima; Kayo Inaba; Koichi Tanaka
Journal:  Clin Dev Immunol       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.